Cargando…

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study

OBJECTIVE: To evaluate the efficacy and safety of degarelix 3-month depot in Japanese patients with prostate cancer. METHODS: In this Phase II, open-label, parallel-group study, 155 Japanese prostate cancer patients were randomized to treatment with degarelix administered subcutaneously at a mainten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozono, Seiichiro, Tsukamoto, Taiji, Naito, Seiji, Ohashi, Yasuo, Ueda, Takeshi, Nishiyama, Tsutomu, Maeda, Hideki, Kusuoka, Hidehito, Akazawa, Rio, Ito, Mototsugu, Akaza, Hideyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421626/ https://www.ncbi.nlm.nih.gov/pubmed/28334771 http://dx.doi.org/10.1093/jjco/hyx011

Ejemplares similares

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
por: Akaza, Hideyuki, et al.
Publicado: (2016)

Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
por: Ueda, Takeshi, et al.
Publicado: (2013)

Mistaken administration of a repeat loading dose of Degarelix leading to acute psychosis
por: Hamdoon, Musaab, et al.
Publicado: (2021)

Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study
por: Tomita, Yoshihiko, et al.
Publicado: (2016)

A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer
por: Suzuki, Kazuhiro, et al.
Publicado: (2014)

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching
por: Onozawa, Mizuki, et al.
Publicado: (2018)

A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
por: Satoh, Takefumi, et al.
Publicado: (2014)

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma
por: Eto, Masatoshi, et al.
Publicado: (2014)

Evaluation of degarelix in the management of prostate cancer
por: Van Poppel, Hendrik
Publicado: (2010)

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score
por: Akaza, Hideyuki, et al.
Publicado: (2013)

Degarelix and its therapeutic potential in the treatment of prostate cancer
por: Doehn, Christian, et al.
Publicado: (2009)

Investigation of the GnRH antagonist degarelix isomerization in biological matrices
por: Ferrazzano, Lucia, et al.
Publicado: (2023)

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
por: Rick, Ferenc G, et al.
Publicado: (2013)

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer
por: Tokiwa, Suguru, et al.
Publicado: (2017)

Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer
por: Sankaran, Sindhu, et al.
Publicado: (2023)

Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen
por: Kato, Hideo, et al.
Publicado: (2017)

Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer
por: Lazenby, Mark
Publicado: (2012)

Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix
por: Ong, Shawn Y., et al.
Publicado: (2015)

A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study
por: Sugimoto, Mikio, et al.
Publicado: (2021)

Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
por: Liu, Stephanie N., et al.
Publicado: (2021)

Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
por: Wallach, Joshua D., et al.
Publicado: (2021)

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis
por: Yan, Jianzhou, et al.
Publicado: (2022)

Asia prostate cancer study (A-CaP Study) launch symposium
por: Akaza, Hideyuki, et al.
Publicado: (2016)

Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial
por: Oyama, Masafumi, et al.
Publicado: (2017)

Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design
por: Reuter, Stephanie E., et al.
Publicado: (2018)

The Effects of Chemical Castration with Degarelix on Bone Turnover: Densitometric and Biomechanics Bone Properties of Male Rats
por: Jayusman, Putri Ayu, et al.
Publicado: (2018)

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design
por: Melloni, Chiara, et al.
Publicado: (2020)

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial
por: Balk, Jiska M, et al.
Publicado: (2015)

Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens
por: Veal, Gareth J., et al.
Publicado: (2016)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Is the Low-Thalidomide Dose MPT Regimen Beneficial?
por: Min, Chang-Ki
Publicado: (2011)

Low Dose Insulin Regimen for Diabetic Coma
por: Asplin, C. M.
Publicado: (1976)

Opioid dose regimen shapes mesolimbic adaptations
por: Cahill, Catherine M.
Publicado: (2020)

Simplified Dosing Regimens for Gentamicin in Neonatal Sepsis
por: D’Agate, S., et al.
Publicado: (2021)

Intra-articular injection of monoiodoacetate induces diverse hip osteoarthritis in rats, depending on its dose
por: Yoh, Satoshi, et al.
Publicado: (2022)

Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients
por: Akaza, Hideyuki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ub54rd67ckv7pnp9erfg9t0pv9